These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 11475495

  • 1. RSV infection and bronchiolitis: who qualifies for prevention?
    Prescrire Int; 2000 Dec; 9(50):173. PubMed ID: 11475495
    [Abstract] [Full Text] [Related]

  • 2. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
    Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network.
    Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
    [Abstract] [Full Text] [Related]

  • 3. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E.
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [Abstract] [Full Text] [Related]

  • 4. Palivizumab in prevention of bronchiolitis: new preparation. Moderate efficacy in some infants.
    Prescrire Int; 2000 Dec; 9(50):171-2, 174. PubMed ID: 11475494
    [Abstract] [Full Text] [Related]

  • 5. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA.
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [Abstract] [Full Text] [Related]

  • 6. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
    Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB, Burgundy Perinatal Network.
    Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
    [Abstract] [Full Text] [Related]

  • 7. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.
    Manzoni P, Paes B, Resch B, Carbonell-Estrany X, Bont L.
    Early Hum Dev; 2012 May; 88 Suppl 2():S34-41. PubMed ID: 22633511
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group.
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [Abstract] [Full Text] [Related]

  • 12. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T, Nakazawa M, Harada K.
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [Abstract] [Full Text] [Related]

  • 13. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
    Grupo de Hospitales Benazuza.
    An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prevention of respiratory syncytial virus infection in high risk infants.
    Prince AM, Jacobs RF.
    J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
    [Abstract] [Full Text] [Related]

  • 17. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 18. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective.
    Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG.
    Can J Cardiol; 2011 Dec; 27(4):523.e11-5. PubMed ID: 21664100
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE, Mahle WT.
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.